{"id":"lrg-002","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Hypothyroidism"},{"rate":"1-5%","effect":"Hyperthyroidism"},{"rate":"1-5%","effect":"Fatigue"},{"rate":"1-5%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Nausea"},{"rate":"1-5%","effect":"Vomiting"},{"rate":"1-5%","effect":"Abdominal pain"},{"rate":"1-5%","effect":"Muscle pain"},{"rate":"1-5%","effect":"Arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, LRG-002 prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.","oneSentence":"LRG-002 is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:42.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT04321460","phase":"PHASE3","title":"Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.","status":"COMPLETED","sponsor":"Sandoz","startDate":"2020-10-01","conditions":"Antibiotic-associated Diarrhea","enrollment":520}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LRG-002","genericName":"LRG-002","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LRG-002 is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}